Scholarlink

<p>Patients with recurrent platinum-resistant ovarian cancer (<b>PROC</b>) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (<b>CSCs</b>). The <b>NCT03949283</b> randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (<b>ORR</b>) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI<sub>95</sub> 39% - 73%), compared to 5% (CI<sub>95</sub> 0% - 11%) for those treated with physician’s choice chemotherapy (<i>p</i> &lt;0.0001). Secondary endpoints of duration of response (<b>DOR</b>) and progression-free survival (<b>PFS</b>) of subjects treated with chemotherapies guided by the ChemoID assay versus physician’s choice chemotherapy were a median of 8 months vs. 5.5 months (<i>p</i> &lt;0.0001), and 11.0 months (CI<sub>95</sub> 8.0– NA) vs 3.0 months (CI<sub>95</sub> 2.0– 3.5) with 27% of hazard ratio (CI95, 0.15–0.49; <i>p</i> &lt;0.001), respectively.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月25日

查看全文
  • Thomas J. Herzog,
  • Thomas C. Krivak,
  • Stephen Bush II,
  • John P. Diaz,
  • Scott Lentz,
  • Navya Nair,
  • Nadim Bou Zgheib,
  • Camille Gunderson-Jackson,
  • Abhijit Barve,
  • Krista L. Denning,
  • Seth T. Lirette,
  • Candace M. Howard,
  • Jagan Valluri,
  • Pier Paolo Claudio

摘要

Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (ORR) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI95 39% - 73%), compared to 5% (CI95 0% - 11%) for those treated with physician’s choice chemotherapy (p <0.0001). Secondary endpoints of duration of response (DOR) and progression-free survival (PFS) of subjects treated with chemotherapies guided by the ChemoID assay versus physician’s choice chemotherapy were a median of 8 months vs. 5.5 months (p <0.0001), and 11.0 months (CI95 8.0– NA) vs 3.0 months (CI95 2.0– 3.5) with 27% of hazard ratio (CI95, 0.15–0.49; p <0.001), respectively.